St. Jude Develops Rapid Breath Test for Bacterial Infections — St. Jude Children's Research Hospital, Inc.

Event summary

St. Jude Children’s Research Hospital and UC San Francisco developed a breath test using carbon-13-enriched mannitol to detect bacterial infections.
The test measures exhaled CO2 via inexpensive infrared scanners, distinguishing bacterial from viral infections or inflammation.
Study published in ACS Central Science on March 18, 2026, demonstrates proof-of-concept for rapid, affordable bacterial infection detection.
Researchers successfully detected signs of myositis, bacteremia, pneumonia, and osteomyelitis in trials.
Funding supported by NIH, Cystic Fibrosis Foundation, and ALSAC, with plans for future clinical studies.

The big picture

The development of a rapid, affordable breath test for bacterial infections addresses a critical gap in diagnostic medicine, where distinguishing bacterial from viral infections often leads to unnecessary antibiotic use. This innovation aligns with broader industry trends toward precision diagnostics and reducing healthcare costs. The test's potential to streamline infection detection could have significant implications for patient outcomes and antibiotic stewardship, particularly in settings with immunocompromised individuals.

What we're watching

Clinical Validation: The pace at which the breath test transitions from proof-of-concept to clinical validation will determine its real-world applicability.
Market Adoption: Whether healthcare providers will integrate this test into urgent care and emergency room settings, reducing unnecessary antibiotic prescriptions.
Competitive Landscape: How this innovation positions St. Jude in the diagnostic testing market, potentially disrupting traditional bacterial infection detection methods.